

Johannes Bloehdorn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7867350/publications.pdf>

Version: 2024-02-01

64
papers

2,354
citations

361045

20
h-index

214527

47
g-index

67
all docs

67
docs citations

67
times ranked

3927
citing authors

#	ARTICLE	IF	CITATIONS
1	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	0.8	257
2	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , 2016, 127, 1559-1563.	0.6	228
3	Cellular origin and pathophysiology of chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2012, 209, 2183-2198.	4.2	227
4	High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 120, 4783-4794.	0.6	179
5	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 969-975.	0.8	177
6	Venetoclax resistance and acquired <i>BCL2</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, e434-e437.	1.7	144
7	High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). <i>Leukemia</i> , 2017, 31, 846-852.	3.3	134
8	Impact of serum storage conditions on microRNA stability. <i>Leukemia</i> , 2012, 26, 2414-2416.	3.3	133
9	Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. <i>Blood</i> , 2020, 135, 2402-2412.	0.6	83
10	Worldwide literature on epidemiology of human alveolar echinococcosis: a systematic review of research published in the twenty-first century. <i>Infection</i> , 2019, 47, 703-727.	2.3	80
11	High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. <i>Leukemia</i> , 2017, 31, 2623-2629.	3.3	72
12	Interleukin-10 receptor signaling promotes the maintenance of a PD-1 ^{int} TCF-1 ⁺ CD8 ⁺ T _H cell population that sustains anti-tumor immunity. <i>Immunity</i> , 2021, 54, 2825-2841.e10.	6.6	57
13	FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL. <i>Blood</i> , 2019, 133, 830-839.	0.6	56
14	IGF1R as druggable target mediating PI3K- $\hat{\gamma}$ inhibitor resistance in a murine model of chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 534-547.	0.6	51
15	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). <i>Haematologica</i> , 2020, 105, 2598-2607.	1.7	44
16	Discovery of Candidate DNA Methylation Cancer Driver Genes. <i>Cancer Discovery</i> , 2021, 11, 2266-2281.	7.7	42
17	Obinutuzumab (GA-101), ibrutinib, and venetoclax (G1Ve) frontline treatment for high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2022, 139, 1318-1329.	0.6	30
18	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. <i>Lancet Oncology</i> , 2019, 20, 1576-1586.	5.1	26

#	ARTICLE	IF	CITATIONS
19	Lamin B1 regulates somatic mutations and progression of B-cell malignancies. <i>Leukemia</i> , 2018, 32, 364-375.	3.3	25
20	Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL. <i>Leukemia</i> , 2020, 34, 115-127.	3.3	23
21	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22
22	The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , 2019, 104, 1004-1015.	1.7	20
23	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. <i>Leukemia</i> , 2016, 30, 1428-1430.	3.3	19
24	Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019, 33, 2183-2194.	3.3	19
25	Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. <i>Leukemia</i> , 2017, 31, 734-738.	3.3	18
26	Stromal cell protein kinase C- β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	18
27	The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. <i>Leukemia</i> , 2015, 29, 2003-2014.	3.3	17
28	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 5395.	5.8	15
29	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 420-425.	0.6	14
30	Simple liver cysts and cystoid lesions in hepatic alveolar echinococcosis: a retrospective cohort study with Hounsfield analysis. <i>Parasite</i> , 2019, 26, 54.	0.8	14
31	MARCKS affects cell motility and response to BTK inhibitors in CLL. <i>Blood</i> , 2021, 138, 544-556.	0.6	14
32	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018, 59, 1614-1623.	0.6	12
33	Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. <i>Haematologica</i> , 2022, 107, 604-614.	1.7	11
34	Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in $\hat{\text{a}}\text{e}^{\text{u}}\text{ltra High-risk}\hat{\text{a}}\text{e}^{\text{u}}\text{CLL}$: Final Results from the CLL2O Phase II Study. <i>Blood</i> , 2014, 124, 1991-1991.	0.6	11
35	Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 1177-1186.	3.3	8
36	Distribution of alveolar echinococcosis according to environmental and geographical factors in Germany, 1992-2018. <i>Acta Tropica</i> , 2020, 212, 105654.	0.9	8

#	ARTICLE	IF	CITATIONS
37	DNA methylation of chronic lymphocytic leukemia with differential response to chemotherapy. <i>Scientific Data</i> , 2020, 7, 133.	2.4	6
38	U-RT1 â€œ A new model for Richter transformation. <i>Neoplasia</i> , 2021, 23, 140-148.	2.3	5
39	S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY. <i>HemaSphere</i> , 2019, 3, 4.	1.2	4
40	Salvage Therapy for Alveolar Echinococcosisâ€”A Case Series. <i>Pathogens</i> , 2022, 11, 333.	1.2	4
41	Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B.. <i>Blood</i> , 2018, 132, 1701-1701.	0.6	3
42	Expression of Cereblon (CRBN) Is Associated with Disease Stage, Genetic Subgroups and Specific Micro-RNAs in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1820-1820.	0.6	3
43	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	0.6	3
44	Follow-up in hepatic alveolar echinococcosis under benzimidazole therapy using computed tomography. <i>Chinese Medical Journal</i> , 2020, 133, 1507-1509.	0.9	2
45	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. <i>Haematologica</i> , 2021, , .	1.7	2
46	P53 and microRNAs in chronic lymphocytic leukemia. <i>Journal of Nucleic Acids Investigation</i> , 2011, 2, 8.	0.5	1
47	NOTCH1 Signaling Is Activated in CLL By Mutations of FBXW7 and Low Expression of USP28 at 11q23. <i>Blood</i> , 2018, 132, 946-946.	0.6	1
48	Genomic Mechanisms of 17p / TP53 Loss in Primary â€œultra High-riskâ€•and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. <i>Blood</i> , 2014, 124, 2184-2184.	0.6	1
49	Venetoclax Resistance in Mantle Cell Lymphoma Is Mediated By BCL-XL and Can be Circumvent By Inhibiting the BH4 Domain of BCL-2. <i>Blood</i> , 2019, 134, 1507-1507.	0.6	1
50	The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1794-1805.	3.3	1
51	CLINICAL PRESENTATION AND MOLECULAR CHARACTERISTICS OF CUTANEOUS DLBCL. <i>Hematological Oncology</i> , 2019, 37, 362-362.	0.8	0
52	MicroRNAs in Leukemia. , 2011, , 269-285.		0
53	Microrna Expression in Fludarabine-Refractory CLL Implicates Independent Mechanisms of Resistance and Is Associated with Response and Progression Free Survival After Alemtuzumab Treatment: Results From the CLL2H Trial.. <i>Blood</i> , 2012, 120, 2874-2874.	0.6	0
54	MicroRNAs in Hematologic Malignancies. , 2014, , 67-95.		0

#	ARTICLE	IF	CITATIONS
55	High-Resolution Genomic Copy Number Analysis on Sequential Samples from the CLL8 Trial: Relation Between Clonal Evolution and Defects in DNA Damage Response?. Blood, 2014, 124, 1964-1964.	0.6	0
56	High Resolution Genomic Profiling of Primary "Ultra High Risk" and Refractory Chronic Lymphocytic Leukemia: Results from the CLL2O Trial. Blood, 2014, 124, 3288-3288.	0.6	0
57	Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 2018, 132, 583-583.	0.6	0
58	Ibrutinib Can Induce Complete Remissions and Sustained Responses in Refractory Cutaneous or Leg-Type Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4237-4237.	0.6	0
59	MYC Pathway Activation Is Frequently Observed in Treatment-Naive CLL and Defines a Subgroup with Particular Benefit from the Addition of Rituximab to Chemotherapy. Blood, 2018, 132, 1866-1866.	0.6	0
60	Characterization of Mechanisms Underlying Acquired Venetoclax-Resistance in Mantle Cell Lymphoma: BDA-366 As a Potential Treatment Option. Blood, 2018, 132, 1580-1580.	0.6	0
61	Clonal Evolution in Chronic Lymphocytic Leukemia is Scant in Relapsed But Accelerated in Refractory Cases. SSRN Electronic Journal, 0, , .	0.4	0
62	Telomere Shortening By Terc Knockout in the Eμ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival. Blood, 2019, 134, 1732-1732.	0.6	0
63	Robust Discovery of Candidate DNA Methylation Cancer Drivers. Blood, 2020, 136, 33-34.	0.6	0
64	Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-13.	0.6	0